What is Pemphigus vulgaris?
Pemphigus vulgaris is a rare, life-threatening autoimmune blistering disease that primarily affects the skin and mucous membranes. The condition occurs when the body’s immune system mistakenly attacks proteins called desmogleins that hold skin cells together, causing painful blisters and erosions. It affects approximately 0.1-0.5 people per 100,000 annually, with onset typically occurring between ages 40-60. While historically fatal, modern treatments have dramatically improved outcomes, though the condition requires lifelong management and significantly impacts quality of life.
Key statistics
| Annual incidence: | 0.1-0.5 per 100,000 people |
| Age of onset: | Most common between 40-60 years |
| Mortality rate: | 5-15% with treatment (historically 90% without treatment) |
| Gender distribution: | Slightly more common in women |
Symptoms
Primary symptoms: Flaccid bullae (soft, fluid-filled blisters), painful mucosal erosions, positive Nikolsky sign, crusted lesions, foul-smelling discharge.
Early symptoms often begin in the mouth with painful sores, ulcers, and difficulty eating or swallowing. These oral lesions may persist for months before skin involvement becomes apparent, leading to delayed diagnosis. Patients frequently experience burning sensations and tenderness in affected areas.
Common symptoms include the development of fragile blisters that rupture easily, leaving behind painful, raw erosions. The positive Nikolsky sign—where gentle pressure causes the skin to separate—is characteristic. Lesions typically appear on the scalp, face, chest, back, and areas subject to friction. The blisters are flaccid rather than tense, distinguishing them from other blistering conditions.
Serious symptoms may include widespread skin involvement covering large body surface areas, secondary bacterial infections, dehydration, electrolyte imbalances, and sepsis. Severe cases can involve the entire oral cavity, pharynx, larynx, and esophagus, making eating, drinking, and speaking extremely difficult.
Causes and risk factors
Pemphigus vulgaris is an autoimmune disease caused by the production of antibodies against desmoglein proteins, specifically desmoglein 1 and 3. These proteins form desmosomes, which are cellular structures that bind skin cells together. When antibodies attack these proteins, the cellular connections break down, leading to blister formation through a process called acantholysis.
Genetic factors play a significant role, with certain HLA (human leukocyte antigen) types, particularly HLA-DRB1 and HLA-DQB1 alleles, increasing susceptibility. The condition shows higher prevalence in certain ethnic groups, including Ashkenazi Jews, people of Mediterranean descent, and individuals from the Middle East and Indian subcontinent.
Environmental triggers may include medications (particularly ACE inhibitors, penicillin, and captopril), viral infections, stress, burns, or other trauma. However, many cases occur without identifiable triggers. The condition is not contagious and cannot be transmitted from person to person.
Prevention
There is no known way to prevent pemphigus vulgaris, as it is an autoimmune condition with complex genetic and environmental factors. The disease is not inherited in a simple Mendelian pattern, and genetic testing for susceptibility is not routinely recommended or clinically useful for family members.
However, individuals with known HLA risk factors who develop persistent oral ulcers should seek early medical evaluation. Avoiding known medication triggers in susceptible individuals may be beneficial, though this requires careful balance with medical necessity. Early recognition and prompt treatment remain the most effective strategies for preventing severe complications.
Complications
Without treatment, pemphigus vulgaris was historically fatal in 90% of cases due to fluid loss, electrolyte imbalances, and overwhelming infections. Even with modern treatment, several serious complications can occur.
Immediate complications include secondary bacterial infections of erosions, sepsis, dehydration, and protein loss through damaged skin. Oral involvement can lead to malnutrition due to difficulty eating and drinking.
Long-term complications may include permanent scarring, particularly in areas of repeated trauma, chronic pain, and psychological impacts including depression and social isolation. Treatment-related complications from long-term corticosteroid use include osteoporosis, diabetes, cardiovascular disease, and increased infection risk. Immunosuppressive therapies may increase the risk of certain cancers and opportunistic infections.
Diagnosis
Diagnosing pemphigus vulgaris requires a combination of clinical presentation, histological examination, and immunological testing. The diagnostic journey often involves multiple specialists and can take months, as early symptoms may be misattributed to other conditions.
Clinical examination focuses on the characteristic flaccid bullae, mucosal erosions, and positive Nikolsky sign. The distribution pattern and appearance of lesions provide important diagnostic clues.
Skin biopsy is essential, showing acantholysis (loss of cell-to-cell adhesion) and intraepidermal blistering. The biopsy should be taken from the edge of a fresh blister for optimal results.
Direct immunofluorescence of perilesional skin demonstrates the characteristic “fish-net” or “chicken-wire” pattern of IgG and C3 deposition between epidermal cells.
Indirect immunofluorescence and ELISA testing detect circulating anti-desmoglein antibodies in the blood. Anti-desmoglein 3 antibodies are associated with mucosal disease, while anti-desmoglein 1 antibodies correlate with skin involvement. Antibody levels often correlate with disease activity and treatment response.
Treatment
Treatment aims to suppress the autoimmune response, promote healing, and prevent complications. The therapeutic approach typically involves systemic immunosuppression combined with supportive care.
First-line treatment traditionally involves high-dose prednisone (1-2 mg/kg/day), though this is increasingly combined with steroid-sparing agents to minimize long-term corticosteroid complications.
Rituximab, a monoclonal antibody targeting B-cells, has emerged as a highly effective treatment. Rituximab is now approved for pemphigus vulgaris and may be used as first-line therapy or in steroid-resistant cases.
Additional immunosuppressants include mycophenolate mofetil, azathioprine, and cyclophosphamide for severe or refractory cases.
Supportive care includes wound care with non-adherent dressings, pain management, nutritional support, and infection prevention. Plasmapheresis or immunoadsorption may be used in severe cases to rapidly reduce antibody levels.
Prognosis
With modern treatment, the 10-year survival rate exceeds 85-90%, a dramatic improvement from the pre-corticosteroid era. However, pemphigus vulgaris remains a serious condition requiring long-term management.
Treatment response varies, with most patients achieving initial control within 2-6 months of appropriate therapy. Complete remission may occur in 30-50% of patients, though this may take several years to achieve. Some patients require lifelong immunosuppression to maintain disease control.
Factors affecting prognosis include age at onset (older patients have worse outcomes), extent of disease at presentation, and response to initial treatment. Early diagnosis and prompt treatment significantly improve outcomes and reduce the risk of complications.
Quality of life
Pemphigus vulgaris profoundly impacts daily life, affecting eating, speaking, personal hygiene, and social interactions. The visible nature of the condition and associated pain can lead to social withdrawal, depression, and anxiety.
Dietary modifications are often necessary, particularly during active phases. Soft, bland foods may be better tolerated when oral lesions are present. Adequate nutrition and hydration are crucial for healing.
Skin care requires gentle cleansing, avoiding trauma, and using appropriate wound dressings. Sun protection is important, as damaged skin may be more susceptible to UV injury.
Mental health support is essential, as the chronic nature of the condition and treatment side effects can significantly impact psychological well-being. Counseling, support groups, and patient education programs can be beneficial.
Work and social adaptations may be necessary during active phases, with some patients requiring extended medical leave or workplace accommodations.
Pregnancy and fertility
Pemphigus vulgaris can complicate pregnancy, and pregnancy may trigger disease flares due to hormonal changes and immune system alterations. Maternal antibodies can cross the placenta, potentially causing transient neonatal pemphigus, though this is usually mild and self-resolving.
Medication considerations are crucial, as many immunosuppressants require careful evaluation during pregnancy. Corticosteroids are generally considered safer than other immunosuppressants, though they carry their own risks. Rituximab use in pregnancy requires careful risk-benefit assessment.
Preconception counseling should address disease optimization, medication adjustments, and pregnancy planning with a multidisciplinary team including dermatology, obstetrics, and pharmacy specialists.
Children
Pemphigus vulgaris is extremely rare in children, with most cases occurring in adults. When it does occur in pediatric patients, it tends to follow a similar course to adult disease but may require modified dosing of medications and careful attention to growth and development impacts from immunosuppressive therapy.
Neonatal pemphigus can occur in infants born to mothers with active disease due to transplacental transfer of maternal antibodies, but this is typically transient and resolves as maternal antibodies are cleared.
When to see a doctor
Urgent medical attention is needed for persistent oral ulcers lasting more than two weeks, particularly if accompanied by difficulty eating or drinking; new onset of fragile blisters that rupture easily; fever with skin lesions; or signs of infection including increased pain, warmth, or purulent discharge.
Routine follow-up should be scheduled for patients with diagnosed pemphigus to monitor disease activity, treatment response, and medication side effects. Regular laboratory monitoring is essential for patients on immunosuppressive therapy.
Regional context
Limited data exists specifically for pemphigus vulgaris prevalence in the Caucasus region (Georgia, Armenia, Azerbaijan) and Eastern Mediterranean. However, the condition is known to have higher prevalence in Mediterranean populations and the Middle East. We invite healthcare professionals and researchers from these regions to contribute their clinical experience and epidemiological data to enhance our understanding of regional disease patterns.
Research and clinical trials
Current research focuses on developing more targeted therapies with fewer side effects. Promising approaches include novel biologics targeting specific immune pathways, chimeric antigen receptor (CAR) T-cell therapy, and improved B-cell depletion strategies.
Recent breakthroughs include the approval of rituximab as first-line therapy and ongoing studies of other anti-CD20 agents. Research into the molecular mechanisms of acantholysis continues to identify new therapeutic targets.
Patients interested in clinical trials can search ClinicalTrials.gov for current studies. The International Pemphigus & Pemphigoid Foundation maintains updated information about research opportunities and emerging treatments.
Frequently asked questions
Is pemphigus vulgaris contagious?
No, pemphigus vulgaris is not contagious. It is an autoimmune disease that cannot be transmitted from person to person through contact, sharing items, or any other means.
Will I need treatment for life?
Many patients require long-term treatment, though some achieve complete remission and can discontinue medications. The duration of treatment varies greatly between individuals and depends on disease severity and treatment response.
Can pemphigus vulgaris be cured?
While there is no definitive cure, pemphigus vulgaris can be effectively controlled with appropriate treatment. Some patients achieve long-term remission, while others require ongoing management to control symptoms.
How quickly does treatment work?
Initial improvement may be seen within days to weeks of starting treatment, but achieving disease control typically takes 2-6 months. Complete healing of lesions and achieving remission may take months to years.
What should I avoid if I have pemphigus vulgaris?
Avoid trauma to the skin, certain medications known to trigger flares (discuss with your doctor), and activities that may cause friction or injury. Maintain good oral hygiene while being gentle with affected areas.
Support and resources
International Pemphigus & Pemphigoid Foundation: https://www.pemphigus.org/
National Organization for Rare Disorders (NORD): https://rarediseases.org/
Orphanet: https://www.orpha.net/
EURORDIS (European Organisation for Rare Diseases): https://www.eurordis.org/
Global Genes: https://globalgenes.org/
Related conditions
Pemphigus foliaceus
Bullous pemphigoid
Mucous membrane pemphigoid
Paraneoplastic pemphigus
Epidermolysis bullosa
Sources: Orphanet (orpha.net), OMIM, GeneReviews (NCBI), WHO ICD-11, relevant guidelines. Informational only; not medical advice. CC BY 4.0.
Cite this page
GMJ News Desk. “Pemphigus vulgaris.” GMJ News — Georgian Medical Journal, 2 June 2026. https://news.gmj.ge/condition/pemphigus-vulgaris/
Licensed under CC BY 4.0. Free to share with attribution to GMJ News.Sources: Orphanet (orpha.net), OMIM, GeneReviews (NCBI), WHO ICD-11, EULAR/ACR guidelines. Schema.org MedicalCondition structured data included.
Was this article helpful?